

SENZAGEN

Wishing all our customers and partners


A SENZATIONAL 2018

SenzaGen
2017
highlights

MARCH

GARDpotency launch for pilot sales during SOT Annual Meeting.

SenzaGen and AstraZeneca initiate technology development collaboration.



JUNE

Global distribution agreement signed with Charles River Laboratories.

Peer-reviewed publications:

- The GARD platform for potency assessment
- Skin Sensitization: Challenging the Conventional Thinking

SEPTEMBER

The team has expanded with lab engineers, Chief Commercial Officer and Chief Scientific Officer.

SenzaGen Listed on Nasdaq First North Stockholm. September 21st, first day of trading for SenzaGen shares.

OCTOBER

All laboratory elements completed in the regulatory part of the validation process for GARDskin.

GARDprotein demonstrates exceptional ability to identify allergens in foodstuff—data presented at scientific conference.

DECEMBER

SenzaGen reports positive results from ring trial in the validation of GARDskin.

JANUARY 2018

Final validation report sent in to Regulatory Authorities, 93,8% accuracy in average over all validation laboratories—best in class.

MARCH 2018

Meet us at the
SOT 57th
Annual Meeting
booth #1851

